Kaleido Biosciences, Inc. (KLDO)
Stock Price:
$6.55 USD
-0.08 (-1.21%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
232.83M |
| Revenue (ttm) |
250,000 |
| Net Income (ttm) |
-79.95M |
| Shares Out |
35.55M |
| EPS (ttm) |
-2.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$6.55 |
| Previous Close |
$6.63 |
| Change ($) |
-0.08 |
| Change (%) |
-1.21% |
| Day's Open |
6.52 |
| Day's Range |
6.40 - 6.74 |
| Day's Volume |
104,120 |
| 52-Week Range |
2.82 - 11.89 |
More Stats
| Market Cap |
232.83M |
| Enterprise Value |
180.29M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.55M |
| Float |
12.20M |
| EPS (basic) |
-2.57 |
| EPS (diluted) |
-2.62 |
| FCF / Share |
-2.22 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.75M |
| Short Ratio |
5.81 |
| Short % of Float |
22.57% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
931.32 |
| PB Ratio |
4.83 |
| Revenue |
250,000 |
| Operating Income |
-78.29M |
| Net Income |
-79.95M |
| Free Cash Flow |
-70.70M |
| Net Cash |
52.54M |
| Net Cash / Share |
1.48 |
| Gross Margin |
100.00% |
| Operating Margin |
-31,314.00% |
| Profit Margin |
-31,978.40% |
| FCF Margin |
-28,281.20% |
| ROA |
-49.68% |
| ROE |
-117.61% |
| ROIC |
-410.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$13.25*
(102.29% upside)
Low
8.00
Current: $6.55
High
19.00
Target: 13.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -86.66 | -60.68 | -27.03 |
| Net Income | -86.33 | -61.74 | -27.56 |
| Shares Outstanding | 25.70 | 5.11 | 4.47 |
| Earnings Per Share | -3.36 | -12.09 | -6.17 |
| Operating Cash Flow | -75.80 | -46.32 | -22.50 |
| Capital Expenditures | -3.59 | -3.00 | -1.41 |
| Free Cash Flow | -79.38 | -49.32 | -23.90 |
| Cash & Equivalents | 73.53 | 78.27 | 28.68 |
| Total Debt | 20.39 | 14.83 | 14.81 |
| Net Cash / Debt | 53.14 | 63.44 | 13.87 |
| Assets | 82.31 | 85.33 | 30.75 |
| Liabilities | 33.42 | 28.34 | 21.93 |
| Book Value | 48.88 | -96.24 | -43.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kaleido Biosciences, Inc. |
| Country |
United States |
| Employees |
91 |
| CEO |
Daniel L. Menichella |
Stock Information
| Ticker Symbol |
KLDO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KLDO |
| IPO Date |
February 28, 2019 |
Description
Kaleido Biosciences, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.